Aktie A12GQZ PRESCIENT THERAPEUTICS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Prescient Therapeutics Limited

Aktien

A12GQZ

AU000000PTX3

PTX

Markt geschlossen - Australian S.E.
Andere Börsenplätze
 08:10:36 15.05.2024 		% 5 Tage % 1. Jan.
0,044 AUD +10,00 % Intraday Chart für Prescient Therapeutics Limited -2,22 % -29,03 %
25.03. Transcript : Prescient Therapeutics Limited - Special Call
23.02. Prescient Therapeutics Limited berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Halbjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Prescient Therapeutics Sees Positive Results in PTX-100 Study
Prescient Therapeutics Limited Announces PTX-100 Trial Update
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center
Prescient Therapeutics Launches $6 Million Share Purchase Plan
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A12GQZ Aktie
  4. Nachrichten Prescient Therapeutics Limited
  5. Andere Sprachen